Prostate-specific Antigen Testing in Men with Disabilities: A Cross-sectional Analysis of the Health Information National Trends Survey

被引:1
|
作者
Leong, Joon Yau [1 ]
Pinkhasov, Ruben [2 ]
Chandrasekar, Thenappan [1 ]
Shapiro, Oleg [2 ]
Daneshvar, Michael [2 ]
Jacob, Joseph [2 ]
Sanford, Thomas [2 ]
Bratslavsky, Gennady [2 ]
Goldberg, Hanan [2 ]
机构
[1] Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Dept Urol, Philadelphia, PA USA
[2] SUNY Upstate Med Univ, Dept Urol, 750 E Adams St, Syracuse, NY 13210 USA
来源
EUROPEAN UROLOGY FOCUS | 2022年 / 8卷 / 05期
关键词
Prostate-specific antigen; Testing; Screening; Prostate cancer; Detection; Disability; SHARED DECISION-MAKING; CARE ACCESS; DEAF; DIAGNOSIS; BELIEFS;
D O I
10.1016/j.euf.2021.07.009
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients with disabilities represent a unique minority population. The incidence of prostate-specific antigen (PSA) testing among this population is unknown.Objective: To compare PSA testing rates and associated predictors among men with and without reported disabilities in the USA. Design, setting, and participants: A cross-sectional study of the Health Information National Trends Survey (HINTS) for the years 2012, 2013, 2017 and 2019 was conducted in men with reported disabilities.Outcome measurements and statistical analysis: Baseline demographics of the entire cohort were stratified based on their reported disabilities (none, disabled, deaf, and blind). Each disability was compared separately and in combination with the cohort without disabilities. Multivariable logistic regression models determined clinically significant predictors of PSA testing in men with disabilities compared with those without.Results and limitations: Overall, 782 (15%) men with disabilities were compared with 4569 (85%) men without disabilities. The former cohort was older with a median (interquartile range) age of65 (56-75) versus 57 (43-67) yr (p < 0.001). On multivariable analysis, men with any disability were less likely to undergo PSA testing (odds ratio 0.77, 95% confidence interval 0.62-0.96, p = 0.018). Variables associated with increased PSA testing included age, having a health care provider, health insurance, and living with a partner.Conclusions: Inequalities in PSA testing exist among men with disabilities in the USA, especially among the deaf and blind, being less likely to undergo PSA testing. Further research is required to identify and deal with any obstacles in the implementation of equal PSA testing in this unique population.Patient summary: In the USA, men with reported disabilities are less likely to undergo PSA testing than patients without reported disabilities.(c) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1125 / 1132
页数:8
相关论文
共 50 条
  • [21] Prostate-Specific Antigen Screening in Smokers: A Comprehensive Analysis Using a National Behavioral Survey
    Harmatz, I. Mitchell
    Alkhatib, Khalid Y.
    Leff, Morgan
    Nolazco, Jose I.
    Michel, Katharine F.
    Slinger, Michelle
    Mclauchlan, Nathaniel
    Cortese, Brian D.
    Roberson, Daniel S.
    Schurhamer, Benjamin
    Lee, Daniel J.
    Malkowicz, S. Bruce
    Trinh, Quoc-Dien
    Bivalacqua, Trinity J.
    Guzzo, Thomas J.
    Pierorazio, Phillip M.
    UROLOGY PRACTICE, 2024, 11 (03) : 547 - 556
  • [22] Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities
    Williams, Naomi
    Hughes, Laura J.
    Turner, Emma L.
    Donovan, Jenny L.
    Hamdy, Freddie C.
    Neal, David E.
    Martin, Richard M.
    Metcalfe, Chris
    BJU INTERNATIONAL, 2011, 108 (09) : 1402 - 1408
  • [23] A population-based survey of prostate-specific antigen testing among California men at higher risk for prostate carcinoma
    Spencer, BA
    Babey, SH
    Etzioni, DA
    Ponce, NA
    Brown, ER
    Yu, HJ
    Chawla, N
    Litwin, MS
    CANCER, 2006, 106 (04) : 765 - 774
  • [24] Information on pros and cons of prostate-specific antigen testing to men prior to blood draw: A study from the National Prostate Cancer Register (NPCR) of Sweden
    Fridriksson, Jon
    Gunseus, Katarina
    Stattin, Paer
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2012, 46 (05): : 326 - 331
  • [25] A Comprehensive National Survey of Prostate-specific Antigen Testing and Prostate Cancer Management in France: Uncovering Regional and Temporal Disparities
    Cussenot, Olivier
    Taille, Yoann
    Portal, Jean-Jacques
    Cancel-Tassin, Geraldine
    Roupret, Morgan
    de la Taille, Alexandre
    Ploussard, Guillaume
    Mathieu, Romain
    Hamdy, Freddie C.
    Vicaut, Eric
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (05): : 978 - 981
  • [26] Blood and urine biomarkers in prostate cancer: Are we ready for reflex testing in men with an elevated prostate-specific antigen?
    Chang, Edward K.
    Gadzinski, Adam J.
    Nyame, Yaw A.
    ASIAN JOURNAL OF UROLOGY, 2021, 8 (04) : 343 - 353
  • [27] Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study
    Melia, J
    Moss, S
    Johns, L
    BJU INTERNATIONAL, 2004, 94 (01) : 51 - 56
  • [28] Prostate-specific antigen testing among young men: an opportunity to improve value
    Lange, Suzanne M.
    Ambrose, Jacob P.
    Flynn, Michael C.
    Lowrance, William T.
    Hanson, Heidi A.
    O'Neil, Brock B.
    CANCER MEDICINE, 2021, 10 (06): : 2075 - 2079
  • [29] How Much Information Do Icelandic Men Receive on Pros and Cons of Prostate-Specific Antigen Testing Prior to Undergoing Testing?
    Eiriksdottir, Valgerdur Kristin
    Baldursdottir, Birna
    Fridriksson, Jon Orn
    Valdimarsdottir, Heiddis B.
    AMERICAN JOURNAL OF MENS HEALTH, 2022, 16 (03)
  • [30] Prostate cancer screening with prostate-specific antigen (PSA) to men over 70 years old in an urban health zone, 2018-2020: A cross-sectional study
    Urquijo-Moraza, A.
    Guinea-Castanares, J.
    Iturralde-Iriso, J. M.
    MEDICINA DE FAMILIA-SEMERGEN, 2023, 49 (01):